How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Ozpolat, Hasan Tahsin
    Stolla, Moritz
    BLOOD TRANSFUSION, 2023, 21 (05) : 369 - 374
  • [32] Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
    Tse, Brandon
    Buchholz, Megan
    Pavenski, Katerina
    PLATELETS, 2023, 34 (01)
  • [33] Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
    Logothetis, Constantine N.
    Patel, Ankita
    Eatrides, Jennifer
    Jaglal, Michael
    Haider, Mintallah
    Visweshwar, Nathan
    Laber, Damian A.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
  • [34] Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
    Peyvandi, Flora
    Cataland, Spero
    Scully, Marie
    Coppo, Paul
    Knoebl, Paul
    Hovinga, Johanna A. Kremer
    Metjian, Ara
    de la Rubia, Javier
    Pavenski, Katerina
    Edou, Jessica Minkue Mi
    De Winter, Hilde
    Callewaert, Filip
    BLOOD ADVANCES, 2021, 5 (08) : 2137 - 2141
  • [35] Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+project)
    Coppo, Paul
    Bubenheim, Michael
    Benhamou, Ygal
    Voelker, Linus
    Brinkkoetter, Paul
    Kuehne, Lucas
    Knoebl, Paul
    Mingot-Castellano, Maria Eva
    Pascual-Izquierdo, Cristina
    de la Rubia, Javier
    Garma, Julio del Rio
    Chaturvedi, Shruti
    Masias, Camila
    Mazepa, Marshall
    Zheng, X. Long
    Sinkovits, Gyoergy
    Reti, Marienn
    Patriquin, Christopher J.
    Pavenski, Katerina
    Boechat, Tiago
    Farias, Joao
    Ribeiro, Eduardo Flavio Oliveira
    Andrade, Michaela Larissa Lobo de
    Veyradier, Agnes
    Joly, Berangere
    Bouzid, Raida
    Sakai, Kazuya
    Matsumoto, Masanori
    Agosti, Pasquale
    Mancini, Ilaria
    Peyvandi, Flora
    Gavriilaki, Eleni
    Stubbs, Matthew
    Hmaid, Amjad
    Cataland, Spero
    Laemmle, Bernhard
    Scully, Marie
    ECLINICALMEDICINE, 2025, 82
  • [36] Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura
    Pavenski, Katerina
    Scully, Marie
    Coppo, Paul
    Cataland, Spero
    Knoebl, Paul
    Peyvandi, Flora
    Hovinga, Johanna A. Kremer
    de la Rubia, Javier
    Khan, Umer
    Marques, Ana Paula
    Gunawardena, Sriya
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (05)
  • [37] Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
    Giannotta, Juri Alessandro
    Artoni, Andrea
    Mancini, Ilaria
    Agosti, Pasquale
    Carpenedo, Monica
    Truma, Addolorata
    Miri, Syna
    Ferrari, Barbara
    De Leo, Pasqualina
    Salutari, Prassede
    Mancini, Giorgia
    Molteni, Alfredo
    Rinaldi, Ermina
    Bocchia, Monica
    Napolitano, Mariasanta
    Prezioso, Lucia
    Cuccaro, Annarosa
    Scarpa, Elisabetta
    Condorelli, Annalisa
    Grimaldi, Daniele
    Massaia, Massimo
    Peyvandi, Flora
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (02) : 704 - 716
  • [38] Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series
    Albanell-Fernandez, Marta
    Monge-Escartin, Ines
    Carcelero-San Martin, Esther
    Viladoms, Gisela Riu
    Ruiz-Boy, Sonia
    Lozano, Miquel
    Soy, Dolors
    Moreno-Castano, Ana Belen
    Diaz-Ricart, Maribel
    Cid, Joan
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (03)
  • [39] Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
    Voelker, Linus A.
    Kaufeld, Jessica
    Miesbach, Wolfgang
    Braehler, Sebastian
    Reinhardt, Martin
    Kuehne, Lucas
    Muehlfeld, Anja
    Schreiber, Adrian
    Gaedeke, Jens
    Toelle, Markus
    Jabs, Wolfram J.
    Oezcan, Fedai
    Markau, Silke
    Girndt, Matthias
    Bauer, Frederic
    Westhoff, Timm H.
    Felten, Helmut
    Hausberg, Martin
    Brand, Marcus
    Gerth, Jens
    Bieringer, Markus
    Bommer, Martin
    Zschiedrich, Stefan
    Schneider, Johanna
    Elitok, Saban
    Gawlik, Alexander
    Gaeckler, Anja
    Kribben, Andreas
    Schwenger, Vedat
    Schoenermarck, Ulf
    Roeder, Maximilian
    Radermacher, Joerg
    Bramstedt, Joern
    Morgner, Anke
    Herbst, Regina
    Harth, Ana
    Potthoff, Sebastian A.
    von Auer, Charis
    Wendt, Ralph
    Christ, Hildegard
    Brinkkoetter, Paul T.
    Menne, Jan
    BLOOD ADVANCES, 2020, 4 (13) : 3085 - 3092
  • [40] Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
    Cardesa-Salzmann, Teresa Marta
    Stephan, Bernhard
    Simon, Arne
    Furtwaengler, Rhoikos
    Schoendorf, Dominik
    Heine, Sabine
    Torfah, Eyad
    Lux, Margaux
    Meyer, Sonja
    Graf, Norbert
    CLINICAL CASE REPORTS, 2022, 10 (05):
12345